Ip Share Discussion Threads

[pierre oreilly] 12/8/2021 09:04

Probably the share buyback, which will drive it to 135p. Nano will take it higher than that when announced.

[wetpantz] 11/8/2021 15:11

Trading volume and share price have risen over past few days, announcement on ONT float imminent? I guessing they'll have it away before end Oct.

[bamboo2] 10/8/2021 22:03

IPGroup hold 38.1% of C-Capture



C-Capture is developing the world's best carbon capture technology - CEO Tom White and Carbon Capture Chemist Rose McCarthy explain the benefits the technology offers and why it is suitable for deployment across a range of applications

[wba1] 10/8/2021 10:43

bamboo2;
re the Artios valuation; the IP results specified that their half year valuation was based on 'anticipated financing', so I think we can safely assume they had foreknowledge of the series c round and based their valuation on it. Whilst the actual may have varied slightly it should be pretty close and, so, their valuation takes account of dilution effects and the price paid by new investors.

The Mission news is very good. Even better recent news is the progress reported by Deepmind on the AI model to identify protein folding. I suspect it will significantly accelerate research across this field. Years ago I played Demis Hassabis when he was the future of British chess (and was squashed). The man is a genius.

[eeza] 10/8/2021 10:42

Thank you, bamboo.
I couldn't read the article, so just posted the link.

[bamboo2] 09/8/2021 23:21

IPGoup hold 18% of Mission Therpeutics

===============================

Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone
9th August 2021/in Press Release /
Mission receives $20 million milestone payment

CAMBRIDGE, UK – 9 August 2021 – Mission Therapeutics (“Mission̶1;), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”;)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration.

In the second major milestone of the Companies’ research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer’s and Parkinson’s disease models. As a result of the nomination, Mission will receive a milestone payment of $20 million from AbbVie.

Alzheimer’s and Parkinson’s diseases are the most common neurological disorders worldwide, with over 50 million people living with dementia and Alzheimer’s disease, and 10 million more with Parkinson’s. While there are treatments to help reduce symptoms, there are no treatments available to help stop or reverse progression.

Both Alzheimer’s and Parkinson’s are associated with the accumulation of misfolded, proteins in the brain, which are believed to cause impaired function and death of nerve cells. DUBs can help to maintain cell health by regulating the degradation of these proteins.

Under the terms of the agreement, first announced in 2018, Mission and AbbVie are collaborating to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases. AbbVie has the option to gain exclusive rights to develop and commercialize inhibitors of selected DUB targets and will pay Mission success-based milestones as well as royalty payments for each commercialized product.

Commenting on the development, Dr Anker Lundemose, Mission’s CEO, said:

“We are delighted to have reached this next major milestone in our collaboration with AbbVie and receive the $20 million milestone – this represents a big step forward for Mission and further highlights DUBs as targets for drug development. The successful and timely progression of two DUB targets into the drug discovery phase is further validation of our platform. We look forward to the continuation of this great neurodegenerative disease collaboration.”;

Dr Eric Karran, Vice President, Neuroscience Discovery Research, AbbVie commented:

“There is an urgent need for treatments that can make tangible and lasting improvements to the lives of Alzheimer’s and Parkinson’s patients. Our collaboration with Mission has the potential to identify novel therapeutic options for neurodegenerative disorders. We have had a great experience working with Mission and are pleased to be able to continue to draw on their valued expertise as we enter the next phase of drug development.”

[p1nkfish] 09/8/2021 21:37

Don't see it as a problem, am I missing something?

[bamboo2] 09/8/2021 21:09

eeza, this is covered in detail in the ONT 2020 accounts [link in header, page 7 and later] and was discussed during the Q&A section of the recent IPGroup presentation.

By April 2021 there was a glut of testing capacity and the Govt ended the contract before the maximum quantity allowable was supplied. Around £48m worth of kit and consumables was supplied, invoiced and paid for in 2021 to various governments.

The LSRT business remains the key focus and driver for growth.

Free access here...
H ttp://webcache.googleusercontent.com/search?q=cache:prqGpKW1t24J:

[bamboo2] 09/8/2021 13:47

wba, there is no harm in trying! At the least it would be interesting to find out what percentage of Artois IPGroup now hold, post results.

Re the Series C funding [27/7/2021], this was post results, so can't really be used for an accurate comparison with the valuation in the latest accounts [30/6/2021]. As I said at the time, it looks like IPGroup have taken a dilution in exchange for others stumping up the cash. The cash lifts Artois' NAV, so the value on IPGroups books will be similar.

[p1nkfish] 09/8/2021 13:37

next barrier about 126.8

[wba1] 09/8/2021 13:03

bamboo2; I tend not to contact companies as I know CEOs will not reveal any state secrets (quite rightly) and will certainly not discuss the accounting tricks they have available. And if (very conservative) insurers had such tricks you can be sure they exist in less conservative sectors.

My surprise on Artios is driven by 2 things; firstly the Series C funding raised $153m (or circa £115m). And yet IP value the whole of Artios at only about £120m in the latest accounts (based on an 11.7% stake valued at £14.1m). Whilst not impossible it seems unlikely. Secondly, I have reverted to my habit of looking at the valuation placed on Artios by other investors, and others such as Arix have placed different (higher) valuation on the company (not huge differences but it proves that valuation is not precise and open to CEO choice).

None of this is that important assuming any debate will ultimately be resolved in exit prices, but it does highlight to me that there is a stronger role for regulatory oversight and rules in such valuations.

[bamboo2] 09/8/2021 09:54

Link to ONT accounts to 31/12/2020 in header.

Outlook, LSRT part of the co growing 80%+ in first six months of 2021.
Confirmation that Management will get up to 6.5% of the co in performance related bonus. Also LAT shares to protect against a takeover in the first three years. This has all been agreed in advance with long term investors.

Since the figures are now in the public domain, earlier than the latest required filing date, could this mean the IPO will come sooner than I suggested?

On the technical side, some of the future developments in product performance look stunning. Watch out Illumina.

edit added, since so much has already been agreed with long term investors, does this point towards IPO management having inside info that could affect the share price? If so, I doubt that we will get any buy backs until ONT's flotation plan sees the light of day.

[bamboo2] 08/8/2021 14:01

wba, I noticed the change as it is one of the few valuations that has been reduced [£3.2m] since December 2020.

The value had previously risen from 2019 to 2020, over doubling, from £8.2m to £17.3m

Corporate events in Artois took place both before and after 30/6/2021

If you want to pursue this, I think you should email IR at the IPO, they are very good at replying.

Maybe you could use the opportunity to also ask about the possible dilution that may have taken place in July?

[wba1] 08/8/2021 11:19

Based on £113m t/o for 2020 I am certainly expecting >£200m forecast for 2021 from ONT in their prospectus.

The surprise for me in the IP numbers was the fall in the Artios value, given developments since January. I can see no obvious driver for it and wonder if anyone has any thoughts? As someone with a background in insurance at board level, and knowing the tricks used in that industry to smooth results from year to year (using reserve manipulation), I wonder if valuations of unquoted stocks are used in a similar way in this sector? I would not expect anyone in IP (or similar companies) to admit to such methods, any more than an insurance CEO would publicly admit to reserve manipulation.

[p1nkfish] 07/8/2021 21:20

First look ram.
Shhh, very interesting.

[rambutan2] 07/8/2021 20:03

p1inkfish, have you looked at SENS?

[bamboo2] 07/8/2021 08:54

Results to 30 June 2021 presentation Powerpoint slides.



Detailed Half year results PDF



ESG Report 2021

[bamboo2] 07/8/2021 08:34

H ttps://www.sharecast.com/news/news-and-announcements/ip-group-launches-share-buyback-as-interim-profits-surge--8056592.html

IP Group launches share buyback as interim profits surge

Intellectual property-based business developer IP Group said on Thursday that it will launch a £20.0m share buyback after witnessing a rise in interim profits.

For the six months ended 30 June, IP Group saw pre-tax profits surge to £116.5m from £11.7m a year earlier as portfolio returns and revenues jumped to £145.5m from £34.2m, respectively.

Hard net asset value rose 9% to £117.9m in the half.

The FTSE 250-listed firm also followed up its maiden final dividend with an interim dividend of 0.48p per share and stated it would now put aside £20.0m toward buying back the shares.

Chief executive Alan Aubrey said: "IP Group has continued to make strong headway in 2021 with much activity in the portfolio.

"We continue to be excited by the prospects for the second half of the year including the opportunities our portfolio businesses have from the renewed focus on innovation and sustainability."

[bamboo2] 07/8/2021 08:30

“In 10 or 20 years, everyone will have their genome sequenced.”



"DNA sequencing is creating a new age of health and medicine that is more personalized and targeted than ever before

Sitting in an office cluttered with books and papers, Dr. Terry Snutch, professor at UBC’s Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, picks up a small rectangular object.

Compact and light enough to carry in a pocket, it could easily be mistaken for a flip phone. But it is, in fact, a portable DNA sequencer — and it costs less than an iPhone 12.

Developed by Oxford Nanopore Technologies with help from Dr. Snutch’s team, the MinION sequencer is being used in BC to screen and track COVID-19 variants of concern. But there’s nothing stopping anyone from purchasing the $1,000 device for their own personal use..."

[bamboo2] 06/8/2021 16:04

pink, I can't see this as a DT, for now at least.
In order to confirm a DT we would need to see an eod close below 110.2

More likely a historical resistance zone centred approx 124 to be worked through.

Some may be disappointed at the lack of an ONT announcement?

[pierre oreilly] 06/8/2021 11:57

Buybacks will drive this to the nav, which iirc is about 135p, at which point the buybacks will stop. Until the nano float adds another 200m to the nav, when they'll restart. All just my view.

[p1nkfish] 06/8/2021 11:34

Coming round to the thought there is a double top from end of May. Needs to breakthrough.

[bamboo2] 05/8/2021 16:36

Athenex,[11%] added to listed holdings in post 1




[Ex-Kuur Pharma] [11%, valued at £5.2m, 30/6/2021]